Singapore markets closed

ICL Group Ltd (ICL)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
4.5600-0.1000 (-2.15%)
At close: 04:00PM EDT
4.5400 -0.02 (-0.44%)
After hours: 06:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.6600
Open4.6000
Bid0.0000 x 2200
Ask0.0000 x 4000
Day's range4.5000 - 4.6100
52-week range4.3000 - 6.7300
Volume511,925
Avg. volume784,033
Market cap5.96B
Beta (5Y monthly)0.59
PE ratio (TTM)9.12
EPS (TTM)0.5000
Earnings dateN/A
Forward dividend & yield0.19 (4.19%)
Ex-dividend date14 Mar 2024
1y target est5.30
  • Business Wire

    ICL Announces First Quarter 2024 Earnings Call

    TEL AVIV, Israel, April 15, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it plans to release first quarter 2024 results prior to the opening of the TASE market on Thursday, May 9, 2024.

  • Business Wire

    ICL Files 2023 Annual Report on Form 20-F

    TEL AVIV, Israel, March 14, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC). Included, for the third year in a row, are Task Force on Climate-related Financial Disclosures (TCFD), which provide information on what ICL is doing to mitigate the risks of climate change and reduce its carbon footprint.

  • Business Wire

    ICL Accelerating Biologicals Portfolio Growth in Brazil with Strategic Acquisition

    TEL AVIV, Israel, February 28, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it has acquired Nitro 1000, a manufacturer, developer and provider of biologicals in Brazil for approximately $30 million. This acquisition marks another meaningful step into the biologicals market, while expanding ICL’s product offerings and positioning the company for further expansions into new and adjacent end-markets.